Paclitaxel injectable emulsion: Phase 2a study of weekly administration in patients with platinum-resistant ovarian cancer

Lissianskaya, A.; Gershanovich, M.; Ognerubov, N.; Golubeva, O.; Pratt, J.

doi:10.1200/jco.2004.22.14_suppl.5047

Cited by 9 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…55 TPGS in a parental formulation has been used in clinical trials and has been the subject of a pharmacokinetic study. 56 In contrast to these, TPGS-DOX-FOL conjugate has a shorter circulation time than the TPGS-DOX conjugate and a longer circulation time than the free DOX. This might be attributed to the targeting property of folate, resulting in increased cellular uptake and decreased presence of the drug in plasma that leads to shorter half-life than the TPGS-DOX conjugate.…”

Section: In Vitro Cytotoxicitymentioning

confidence: 99%

Doxorubicin conjugated to D‐α‐tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy

Anbharasi¹,

Cao²,

Feng³

2010

J Biomedical Materials Res

View full text Add to dashboard Cite

This research developed a prodrug strategy to conjugate doxorubicin (DOX) to D-alpha-tocopheryl polyethylene glycol succinate (TPGS) and folic acid (FOL) for targeted chemotherapy to enhance the therapeutic effects and reduce the side effects of the drug. We synthesized two conjugates, TPGS-DOX and TPGS-DOX-FOL, to quantitatively evaluate the advantages of TPGS conjugation and FOL conjugation through passive and active targeting effects. The successful conjugation was confirmed by (1)H nuclear magnetic resonance spectroscopy and Fourier transform infrared spectroscopy. The in vitro drug release was found pH dependent, which is in favor of cancer treatment. The in vitro cellular uptake and cytotoxicity were evaluated with MCF-7 breast cancer cells. It was found that the cellular uptake of DOX increased 15.2% by TPGS conjugation and further 6.3% by FOL conjugation after 0.5-h cell culture. The IC(50) after 24-h cell culture with MCF-7 cancer cells showed that TPGS-DOX conjugate could be 1.19-fold effective versus DOX and that TPGS-DOX-FOL could be 38.6-fold effective than TPGS-DOX and thus 45.0-fold more effective versus DOX. In vivo experiment showed that the half-life of TPGS-DOX and TPGS-DOX-FOL were increased 3.79- and 3.9-fold than the free DOX, and the area under the curve were increased 19.2- and 14.5-fold than the DOX, respectively. The biodistribution data showed that TPGS-DOX and TPGS-DOX-FOL significantly lowered drug accumulation in the heart, thereby reducing the cardiotoxicity, which is the main side effect of the DOX. Furthermore, TPGS-DOX can limit, and TPGS-DOX-FOL can further deduce, the gastrointestinal side effect of the drug.

show abstract

Section: In Vitro Cytotoxicitymentioning

confidence: 99%